Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

177-Lu PSMA imaging and therapy

Next Previous
X
Search
Drug Profile

177-Lu PSMA imaging and therapy

Alternative Names: 177-Lutetium-PSMA-I&T - Curium; 177Lu-PSMA-I&T; 177LU-PSMA-I&T; Lu-177-PSMA-I&T; Lutetium-177 prostate specific membrane antigen I&T; Lutetium-177 PSMA I&T; Lutetium-177-PSMA-imaging-and-therapy

Latest Information Update: 27 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curium Pharma
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 27 Nov 2023 Curium completes enrolment in its phase III ECLIPSE trial for Prostate cancer (Hormone refractory, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Italy, Spain, France (IV)
  • 07 Jun 2023 Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori plans a phase II LUST trial for Prostate cancer (Second-line therapy or greater; Hormone refractory; Metastatic disease; Late-stage disease) in June 2023 (IV) (NCT05893381)
  • 14 Mar 2023 Phase-III clinical trials in Prostate cancer (Hormone refractory, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy, Spain, France (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top